News
Aug 30
Deciphering human astrocyte-neuron crosstalk in Alzheimer's disease
A new project of the Arranz Lab awarded by the Alzheimer's Association
The Alzheimer's Association (ALZ.ORG) leads the way to end Alzheimer's and all other dementia by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.The Alzheimer's Association Research Grant (AARG) award aims to fund early-career investigators who are less than 15 years past their doctoral degree or post-residency (M.D. or D.O.).
The laboratory of Humanized Models of Disease, led by Ikerbasque Principal Investigador, Dr. Amaia Arranz Mendiguren got one of the Alzheimer's Association Research Grant (AARG) in the call 2021.
Jul 22
ACHUCARRO and the Cajal Institute created an associated unit
The collaboration framework will allow partnerships in neuron-glia research, training and innovation
Achucarro Basque Center for Neuroscience (ACHUCARRO) and the Cajal Institute (CSIC - Spanish Council for Scientific Research) subscribed a collaboration agreement to create an "Associated Unit" to jointly advance in the knowledge about neuron - glia interactions in health and disease.
Jul 1
Open call for experienced neuroscientists
We just launched a selection process to hire new researcher(s) in Neuro-Glial Systems Neuroscience
We published an open call to select applications for Group Leader position(s), to develop a new line on systems neuroscience, to study structure and function of neuro-glial circuits and systems.
Apr 12
Dr. Jekyll and Mr. Hyde: what changes in a stem cell to become malignant?
José R. Pineda wrote about his research for MappingIgnorance.org
Research in oncology advances very fast and currently machine-learning-based expert systems exist for the pathologist to support the diagnosis of tumors of unknown origin or even deep comprehension of the role of both immunotherapy and tumor heterogeneity in immune-tumor interactions.
Mar 31
Subcellular specificity of cannabinoid effects in stratonigral circuits
Edgar Soria-Gomez publishes this article in Neuron, started back in his postdoc in Bordeaux
The recreational and therapeutic uses of cannabinoid compounds are increasing around the world. They have been proposed to control pain sensitivity in clinical settings. However, due to significant side effects, such as cognitive impairments and motor dysfunctions, the medicinal exploitation of these drugs and the safety of their recreational use are under intense debate. The main psychoactive component of the cannabis sativa (marijuana) plant is delta-9 tetrahydrocannabinol or THC, which, in the brain, acts mainly by activating cannabinoid receptors type-1 (CB1). The pharmacological activation of the CB1 receptor affects motor control in experimental animals, while in humans the cataleptic effects are considered one of the main causes of traffic accidents due to cannabis use. Therefore, understanding the mechanisms of cannabinoid-induced therapeutic and adverse effects is vital for the safest use of these compounds, but the underlying cellular and molecular mechanisms are poorly understood.